Introduction
Carbonic anhydrases (CA, EC 4.2.1.1) are zinc metalloenzymes that catalyze the reversible hydration of carbon dioxide (CO 2 ) to bicarbonate (HCO 3 -) and a proton (H + ), Scheme 1. 1 This physiological equilibrium underpins pH homeostasis, ion transport and fluid secretion. There are 12
catalytically active isoforms of CA characterized in humans; five isozymes are cytosolic (CA I, II, III, VII and XIII), two are found in mitochondria (CA VA and VB), one is secreted (CA VI) and four are transmembrane anchored with an extracellular facing active site (CA IV, IX, XII and XIV).
These isozymes differ in tissue distribution, catalytic activity and expression profiles, a situation that allows medicinal chemists an opportunity to develop strategies for the selective targeting of CA isozymes of interest with small molecules. CA inhibitors have now been a mainstay of human clinical intervention for several decades, with at least 25 clinically used drugs known that are CA inhibitors. 2 Despite this longevity, the CA enzyme family continues to capture the attention of drug discovery scientists and clinicians as the knowledge regarding the therapeutic implications associated with this enzyme class continues to grow.
2, 3
Scheme 1. Catalytically active CA enzymes catalyze the reversible hydration of carbon dioxide to
give bicarbonate and a proton. is expressed in a selection of normal tissues. 4, 5 The disruption of CA IX and/or XII-mediated pH homeostasis has been shown to generate a cancer-cell selective cytotoxic environment. 6, 7 Significantly, this constitutes a new mechanism of action that may be targeted in the context of developing next generation cancer therapeutics. 8 G250 is a monoclonal antibody that first underwent clinical trials in 1993, 9 long before its antigen was identified as CA IX in 2000. 10 CA IXspecific monoclonal antibodies are presently in Phase III clinical development as both therapeutic and diagnostic agents. 8 The results from targeting CA IX with antibodies have advanced our understanding of the pivotal role of CAs in cancer, underpinning the impetus to assess the therapeutic potential of CA IX and XII inhibition using small molecules. CA-relevant animal models of tumors are only recently available, and as a result the first small molecule CA inhibitors have commenced preclinical development. 8 Transmembrane CA XIV expression is abundant in eye, brain, kidney, colon, small intestine, urinary bladder, liver, and spinal cord where it has a role in buffering to regulate acid-base balance, CA XIV is not associated with tumors. 11, 12 The therapeutic implications of inhibition (or activation) of CA XIV are less well described than for CA IX and XII, and relatively few studies have identified inhibitors of this isozyme or attempted to address selectivity for/against this isozyme. [13] [14] [15] The ensuing drug discovery pipeline challenges that lay ahead for anticancer CA inhibitors imply that drug-like small molecules that selectively target CA IX and XII over off-target CAs will be required to address the growing interest in the potential clinical applications of this enzyme class in oncology. 3 The same rationale applies to CA XIV inhibitors, for which there are presently few potent inhibitors and no selective inhibitors.
The classical small molecule CA inhibitors are primary aryl sulfonamide compounds (R-SO 2 NH 2 ), the sulfonamide anion (R-SO 2 NH -) coordinates to the CA active site Zn 2+ and blocks the endogenous substrates from binding. 1, 2 CAs are a challenging drug target for developing isozyme selective inhibitors as the active site of different isozymes is structurally similar. However CA IX and XII hold distinguishing features that provide an opportunity for selective inhibition by tuning the physicochemical properties of small molecule inhibitors. First, hypoxic tumors overexpress CA IX and XII while many healthy tissues lack these isozymes. 4, 5 Second, CA IX and XII have an extracellular enzyme active site. The properties of small molecules may be modified to take advantage of the cell lipid membrane as a barrier that separates target (extracellular) from off-target (cytosolic) CAs, and CA inhibitors with poor membrane permeability may selectively target CA IX and XII over intracellular CAs. The 'tail' approach for CA inhibitor development involves adding tail groups to the R-SO 2 NH 2 scaffold to enhance physicochemical properties of the inhibitor whilst assisting isozyme selectivity. 16 Using this approach CA inhibitors that incorporate a hydrophilic moiety have been developed with limited membrane permeability. [16] [17] [18] [19] [20] [21] [22] [23] Such compounds are useful as tools to study the role of CA in cancer biology. Primary sulfonamides that incorporate a thiourea linker between the aromatic benzene sulfonamide moiety and the tail moiety have shown excellent inhibition of a selection of CA isozymes, and this class of inhibitors has been developed as CA IXselective imaging agents. [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] In this paper we combine these two aforementioned strategies to synthesize carbohydrate-based (hydrophilic tail moiety), thiourea-bridged (robust linker to tail) all examples the isothiocyanate reacting partner comprises the sulfonamide, with the isothiocyanate functional group introduced using the highly toxic reagent thiophosgene (CSCl 2 ). [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] In this study we employ the 'reverse polarity' approach; the advantage of this being two-fold: (i) glycosyl isothiocyanates are readily synthesized from inexpensive per-O-acetylated sugars using convenient reagents in comparison to thiophosgene, and (ii) as numerous benzene sulfonamide compounds possessing also a primary amine functional group are commercially available, these compounds require no synthetic manipulation prior to use. To the best of our knowledge this is the first time the reverse polarity synthetic strategy has been used to prepare thiourea-bridged CA inhibitors. The amino sulfonamide compounds (1-3), as well as 4-hydrazidobenzene sulfonamide (4), a compound we had previously synthesized, 36, 37 were included as amino building blocks in this study, Chart 1. under Lewis acid catalysis in dichloromethane (a mild one-step procedure), 39 Scheme 1. The latter method was preferred as it avoided the complication of generating and then separating a mixture of target glycosyl isothiocyanate and unwanted glycosyl thiocyanates. Per-O-acetylated maltose and lactose starting materials were prepared from the free sugar precursor using the standard Oacetylation reaction conditions with acetic anhydride and sodium acetate. The target thioureabridged compounds 9-24 were synthesized by the reaction of glycosyl isothiocyanate building blocks 5-8 with an equimolar amount of amine partner 1-4 in acetonitrile at 40 °C, Scheme 1.
Sulfonamides 1 and 4 were less reactive than sulfonamides 2 and 3 so excess 1 and 4 was utilized to improve the product yields. Reactions proceeded with the retention of the stereochemistry at the anomeric centre. Deacetylation of the sugar moieties of compounds 9-24 was achieved using 0. are also provided. Table 2 shows the selectivity data for the thiourea library compounds at transmembrane CAs (IX, XII and XIV) over off-target CAs (I and II), the K i ratios are indicative of isozyme selectivity for transmembrane CAs. for CA XII over CA I by one to three orders of magnitude, with the exception of one compound (compound 27 was non-selective as it has a low CA I inhibition K i of 9 nM). About half of the glycoconjugate compounds were also selective for CA XII over II, notably many of the free sugars 
Isozyme hCA XIV.
There are few benzene sulfonamide compounds for which CA XIV inhibition has been determined, however from these studies it has been shown that this isozyme is more resistant to inhibition than CA IX and XII. 13, 14 The simple parent sulfonamide compounds 1-3
have CA XIV K i s of 2900-5400 nM, much less than for the other transmembrane CAs. The thiourea-bridged glycoconjugate sulfonamides of the present study provide complex structures with significant variation in hydrogen bonding propensity, steric bulk and hydrophobic character. As for cancer-associated CAs, this potency-selectivity profile is necessary for the provision of good lead compounds to assess the biological implications of CA XIV inhibition.
Compound Solubility.
Poor drug solubility may lead to poor absorption and bioavailability following oral dosing, hence solubility is an important physicochemical property in drug discovery. 43 The free sugar thioureido glycoconjugates 25-40 exhibited very good water solubility (> 20 mg/mL). Log P represents intrinsic lipophilicity and compounds with Log P < 0 typically have good solubility. 43 The calculated Log P (cLog P) values for the thiourea bridged glycoconjugate CA inhibitors 9-40 are presented in Table 3 
General procedure 2: Deprotection of thiourea-bridged glycoconjugates (9-24  25-40).
Deprotected compounds 25-40 were prepared by dissolving the corresponding per-O-acetylated precursor 9-24 in anhydrous methanol and treating with methanolic sodium methoxide (25% w/v, 0.1 M final concentration, pH 9-12) at room temperature. Reactions were found to be complete within 30 minutes to 2 h by TLC. Neutralization of the reaction mixture by Amberlite IR-120 acidic ion exchange resin, followed by filtration and evaporation of the filtrate, followed by dissolving the residue in water and lyophilization afforded pure material by 1 H NMR and 13 C NMR spectroscopy.
Yields 86 -95 %.
N-[4-(Aminosulfonyl)phenyl]-N'-(2′,3′,4′,6′-tetra-O-acetyl-D-glucopyranosyl)thiourea (9)
The title compound 9 was prepared from amine 1 and isothiocyanate 5 according to general 
N-[4-(Aminosulfonyl)benzyl]-N'-(2′,3′,4′,6′-tetra-O-acetyl-D-galactopyranosyl)thiourea (14)
The title compound 14 was prepared from amine 2 and isothiocyanate 6 according to general 
N-[4-(Aminosulfonyl)phenethyl]-N'-(2′,3′,4′,6′-tetra-O-acetyl-D-

galactopyranosyl)thiourea (15)
The title compound 15 was prepared from amine 3 and isothiocyanate 6 according to general 
N-[4-(Aminosulfonyl)phenylhydrazido]-N'-(2′,3′,4′,6′-tetra-O-acetyl-D-
galactopyranosyl)thiourea (16)
The title compound 16 was prepared from amine 4 and isothiocyanate 6 according to general 
N-[4-(Aminosulfonyl)phenyl]-N'-(2′,2′′,3′,3′′,4′′,6′,6′′-hepta-O-acetyl-D-
maltosyl)thiourea (17)
The title compound 17 was prepared from amine 1 and isothiocyanate 7 according to general 
4.1.13.
N-[4-(Aminosulfonyl)benzyl]-N'-(2′,2′′,3′,3′′,4′,6′,6′′-hepta-O-acetyl-D-
maltosyl)thiourea (18)
The title compound 18 was prepared from amine 2 and isothiocyanate 7 according to general 
N-[4-(Aminosulfonyl)phenylethyl]-N'-(2′,2′′,3′,3′′,4′′,6′,6′′-hepta-O-acetyl-D-
maltosyl)thiourea (19)
The title compound 19 was prepared from amine 3 and isothiocyanate 7 according to general 
4.1.15.
N-[4-(Aminosulfonyl)phenylhydrazido]-N'-(2′,2′′,3′,3′′,4′′,6′,6′′-hepta-O-acetyl-D-
maltosyl)thiourea (20)
The title compound 20 was prepared from amine 4 and isothiocyanate 7 according to general 
N-[4-(Aminosulfonyl)phenyl]-N'-(2′,2′′,3′,3′′,4′′,6′,6′′-hepta-O-acetyl-D-
lactosyl)thiourea (21)
The title compound 21 was prepared from amine 1 and isothiocyanate 8 according to general 
N-[4-(Aminosulfonyl)phenethyl]-N'-(2′,2′′,3′,3′′,4′′,6′,6′′-hepta-O-acetyl-D-
lactosyl)thiourea (23)
The title compound 23 was prepared from amine 3 and isothiocyanate 8 according to general 
N-[4-(Aminosulfonyl)phenyl]-N'-(β-D-glucopyranosyl)thiourea (25)
The title compound 25 was prepared from compound 9 according to general procedure 2 to give a 
N-[4-(Aminosulfonyl)phenethyl]-N'-(β-D-glucopyranosyl)thiourea (27)
The title compound 27 was prepared from compound 11 according to general procedure 1 to give a white solid. 
N-[4-(Aminosulfonyl)phenylhydrazido]-N'-(β-D-glucopyranosyl)thiourea (28)
The title 
N-[4-(Aminosulfonyl)benzyl]-N'-(β-D-galactopyranosyl)thiourea (30)
The 
N-[4-(Aminosulfonyl)phenylhydrazido]-N'-(β-D-galactopyranosyl)thiourea (32)
The title 72.4, 71.1 (C-2', C-4, C-4' or C-5), 68.7 (C-3'), 60.9 (C-6), 60.8 (C-6'), assignments were confirmed by 1 H-13 C HSQC.
Carbonic anhydrase inhibition assay
An SX.18MV-R Applied Photophysics stopped-flow instrument has been used for assaying the CA I, II, IX, XII and XIV CO 2 hydration activity. 46 Phenol red (at a concentration of 0.2 mM) has been used as indicator, working at the absorbance maximum of 557 nm, with 10 mM Hepes (pH 7.5) as buffer, 0.1 M NaClO 4 (for maintaining constant the ionic strength -this anion is not inhibitory),
following the CA-catalyzed CO 2 hydration reaction for a period of 10 -100 s. Saturated CO 2 solutions in water at 20 ºC were used as substrate. Stock solutions of inhibitors were prepared at a concentration of 10 -50 mM (in the assay buffer) and dilutions up to 1 nM were done with the assay buffer mentioned above. Inhibitor and enzyme solutions were preincubated together for 15 min at room temperature prior to assay, in order to allow for the formation of the E-I complex. The inhibition constants were obtained by non-linear least-squares methods using PRISM 3. The curvefitting algorithm allowed us to obtain the IC 50 values, working at the lowest concentration of substrate of 1.7 mM), from which K i values were calculated by using the Cheng-Prusoff equation.
The catalytic activity (in the absence of inhibitors) of these enzymes was calculated from
Lineweaver-Burk plots and represents the mean from at least three different determinations.
Enzyme concentrations were 10.3 nM for CA I and CA II, 12 nM for CA IX, 15 nM for CA XII and 13 nM for CA XIV. Enzymes used here were recombinant ones.
